Medtronic plc (BUL:2M6)
Bulgaria · Delayed Price · Currency is BGN · Price in EUR | Market Cap | 183.97B -9.3% |
| Revenue (ttm) | 62.51B +9.8% |
| Net Income | 8.71B +12.3% |
| EPS | 6.76 +12.1% |
| Shares Out | n/a |
| PE Ratio | 21.12 |
| Forward PE | 14.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 76.18 |
| Day's Range | n/a |
| 52-Week Range | 63.34 - 91.49 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 24, 2026 |
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and rem... [Read more]
Financial Performance
In fiscal year 2026, Medtronic's revenue was $36.36 billion, an increase of 8.43% compared to the previous year's $33.54 billion. Earnings were $4.80 billion, an increase of 2.98%.
Financial numbers in USD Financial StatementsNews
Why Medtronic's $4 Billion MiniMed Exchange Offer Is Losing Its Allure
The tax-free exchange offer allows Medtronic investors to swap their shares for MiniMed shares held by Medtronic in what Wall Street calls a split-off.
Medtronic’s Altaviva and Symplicity Spyral Systems granted Category I CPT Codes
Medtronic (MDT) announced that the American Medical Association approved new Category I Current Procedural Terminology – CPT – codes for two of its technologies: Altaviva implantable tibial neuromodul...
Medtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems
Coding approvals reflect growing clinical evidence and physician adoption of Medtronic solutions addressing urge urinary incontinence and hypertension GALWAY, Ireland, Oct. 1, 2026 /PRNewswire/ -- Me...
Medtronic announces FDA clearance and CE Mark for Affera Prism-2 software
Medtronic (MDT) announced regulatory milestones for software used with two cardiac ablation platforms. This includes FDA clearance and CE Mark for the latest Affera Prism-2 Mapping Software. The compa...
Medtronic announces regulatory milestones for newest cardiac mapping and ablation software
FDA clearance and CE Mark for latest Affera™ Prism-2 Mapping Software expand cardiac mapping capabilities CE Mark for PulseSelect ProxBox™ Adapter with Proximity Indicator software adds real-time tiss...
Medtronic gets FDA clearance of LigaSure RAS Maryland jaw device on Hugo system
Medtronic (MDT) announced the FDA has cleared the LigaSure RAS Maryland jaw device for use with the Hugo robotic-assisted surgery, or RAS, system. The clearance expands the instruments available on…
Medtronic announces FDA clearance for LigaSure™ RAS Maryland instrument on the Hugo™ RAS system
Trusted vessel-sealing technology used in more than 45 million procedures worldwide is now cleared for robotic-assisted surgery in the U.S. GALWAY, Ireland, Sept. 16, 2026 /PRNewswire/ -- Medtronic (N...
Medtronic Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong acute procedure volumes, AI-driven innovation, and robust growth in key franchises are fueling sustained top-line expansion. Strategic investments in robotics and portfolio optimization, along with operational improvements, support margin expansion and a positive outlook, with further details expected at the upcoming Investor Day.
MiniMed files S-4 in connection with Medtronic exchange offer
MiniMed (MMED) announced that it has filed a Form S-4 Registration Statement with the SEC in connection with Medtronic’s (MDT) offer to exchange up to 225,361,295 shares of MiniMed common…
Medtronic launches exchange offer to complete separation of MiniMed
Medtronic (MDT) announced that it has commenced an exchange offer to split off at least 80.1% of the shares of MiniMed Group (MMED). MiniMed, formerly Medtronic’s Diabetes business, completed its…
Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.
Medtronic shareholders can exchange their Medtronic ordinary shares for shares of MiniMed Provides Medtronic shareholders with option for a generally tax-free exchange for U.S. federal income tax pu...
MiniMed Files Form S-4 Registration Statement in Connection with Medtronic Exchange Offer Announcement
NORTHRIDGE, Calif., Sept. 14, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) announced that it has filed a Form S-4 Registration Statement today with the Securities and Exchange Commission (the "SEC") in...
Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead
CNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy ...
Medtronic Transcript: Wells Fargo 21st Annual Healthcare Conference
MedTech innovation is accelerating, driven by AI, robotics, and new therapies that expand patient access and improve outcomes. Strong Q1 growth is supported by high-performing franchises and investments, with Cardiac Ablation, hypertension, and surgical robotics as key drivers. The company will detail new opportunities at its upcoming Investor Day.
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective...
Medtronic executives to speak at upcoming investor conferences
GALWAY, Ireland, Sept. 4, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences: 2026 Wells...
Medtronic price target raised to $92 from $78 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Medtronic (MDT) to $92 from $78 and keeps a Hold rating on the shares.
Medtronic price target raised to $110 from $100 at UBS
UBS raised the firm’s price target on Medtronic (MDT) to $110 from $100 and keeps a Buy rating on the shares.
Medtronic price target raised to $115 from $100 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Medtronic (MDT) to $115 from $100 and keeps an Outperform rating on the shares. Cardiovascular products continue to drive Medtronic’s…
Medtronic price target raised to $99 from $86 at Truist
Truist raised the firm’s price target on Medtronic (MDT) to $99 from $86 and keeps a Hold rating on the shares. The company reported a solid Q1 revenue beat and…
Medtronic price target raised to $104 from $102 at Wells Fargo
Wells Fargo raised the firm’s price target on Medtronic (MDT) to $104 from $102 and keeps an Overweight rating on the shares. The firm notes the company reported a strong…
Medtronic price target raised to $110 from $95 at BofA
BofA raised the firm’s price target on Medtronic (MDT) to $110 from $95 and keeps a Buy rating on the shares. Almost every business unit ex-CAS has a growth driver…
Medtronic price target raised to $95 from $80 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Medtronic (MDT) to $95 from $80 and keeps a Hold rating on the shares. Medtronic “delivered on its promise” for…
Medtronic price target raised to $100 from $91 at Baird
Baird raised the firm’s price target on Medtronic (MDT) to $100 from $91 and keeps a Neutral rating on the shares. The firm updated its model following results which showed…